Crinetics Pharmaceuticals (CRNX) Q2 2024 earnings summary

Executive summary

• Positive phase II results for atumelnant in congenital adrenal hyperplasia and Cushing's disease were presented at ENDO 2024, reinforcing its potential as a best-in-class therapy.

• Paltusotine's PATHFNDR phase III program in acromegaly showed stable biochemical control and low breakthrough symptoms, with NDA submission on track for 2024 and anticipated launch in 2025.

• Early-stage pipeline progress includes selected development candidates for hyperparathyroidism and ADPKD, with IND-enabling studies underway.

• Strategic partnership with Radionetics Oncology and Eli Lilly could yield significant non-dilutive funding and validates the discovery platform.

• CFO Marc Wilson announced his departure for personal reasons; a search for his successor is underway.

Financial highlights

• Ended Q2 2024 with $863 million in cash, cash equivalents, and investments, projected to fund operations into 2028.

• Q2 2024 research and development expenses were $58.3 million, up from $40.6 million year-over-year.

• General and administrative expenses rose to $24.8 million from $13.3 million year-over-year.

• Net loss for Q2 2024 was $74.1 million, compared to $51.0 million in Q2 2023.

• Revenues were $0.4 million, down from $1.0 million year-over-year, primarily from licensing arrangements.

Outlook and guidance

• NDA submission for paltusotine in acromegaly expected in H2 2024, with commercial launch anticipated in 2025.

• Phase III trial for paltusotine in carcinoid syndrome planned to start by end of 2024.

• Additional phase II data for atumelnant in CAH and Cushing’s disease expected later in 2024, with phase III design discussions to follow.

• IND filing for the PTH antagonist program anticipated in 2025.

• Commercial readiness for multiple launches planned through 2026+ pending regulatory milestones.